Home › NDC Lookup › RxCUI directory › RxCUI 2664901

Motixafortide 62 MG Injection — RxCUI 2664901

Name: Motixafortide 62 MG Injection (RxCUI 2664901)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2664901 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2664901

Official nameMotixafortide 62 MG Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asmotixafortide 62 MG (as motixafortide acetate) Injection

FDA products mapped2

Package NDCs mapped2

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How Motixafortide 62 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Motixafortide 62 MG Injection RxCUI 2664901 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Motixafortide 2664896 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Aphexda 2664902 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Motixafortide Injection 2664900 SCDF
- Motixafortide Injectable Product 2664899 SCDG
- Motixafortide Injection [Aphexda] 2664905 SBDF
- Aphexda Injectable Product 2664904 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Motixafortide 62 MG 2664898 SCDC
- Motixafortide 62 MG Injection [Aphexda] 2664906 SBD
- Motixafortide 62 MG [Aphexda] 2664903 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Motixafortide 62 MG SCDC · 2664898
Motixafortide Injection SCDF · 2664900
Motixafortide Injectable Product SCDG · 2664899

Brand-Name Concepts

Motixafortide 62 MG Injection [Aphexda] SBD · 2664906
Motixafortide 62 MG [Aphexda] SBDC · 2664903
Motixafortide Injection [Aphexda] SBDF · 2664905
Aphexda Injectable Product SBDG · 2664904
Aphexda BN · 2664902

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 2664901 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
73441-0062-01	1 VIAL, GLASS in 1 CARTON (73441-062-01) / 1.7 mL in 1 VIAL...	APHEXDA	Gamida Cell Inc.	2025-06-15
82737-0073-01	1 VIAL, GLASS in 1 CARTON (82737-073-01) / 1.7 mL in 1 VIAL...	Aphexda	BioLineRx USA Inc	2023-09-08

Observed labelers: BioLineRx USA Inc (1) · Gamida Cell Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J2277	Inj, motixafortide, 0.25 mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.